×

NeoStem and Progenitor Cell Therapy (PCT) to Present at Multiple April Conferences

NeoStem Inc. Logo

NEW YORK, April 1, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in April.

Kingston Advisors Dearborn Annual New York Healthcare Investment Forum

  • Date and Time: Monday, April 7, 2014, 9:30 AM EDT
  • Venue: W Times Square, 1567 Broadway, New York, NY
  • Topic: Company Presentation

Workshop: Automation of GMP Cell Production

  • Date and Time: Tuesday, April 15, 2014, 9:15 AM EDT
  • Venue: McMaster University, Hamilton, Ontario
  • Speaker: Robert Shaw, Vice President, Commercial Development, PCT
  • Topic: Beyond the Boutique: Towards a Vision for Advancing the Global Cell Therapy Industry

The 18th International Vascular Biology Meeting (IVBM)

  • Date and Time: Thursday, April 17, 2014, 2:15 – 4:15 PM JST
  • Venue: Miyakomesse, Kyoto, Japan
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Therapeutic Angiogenesis and Regeneration
  • Website: www2.convention.co.jp/ivbm2014/greeting/index.html

GTC Stem Cell Summit

  • Date and Time: Thursday, April 24, 2014, 10:45 AM EDT
  • Venue: Hyatt Regency Cambridge, 575 Memorial Drive, Cambridge, MA
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Advances in Adult & Pluripotent Stem Cells
  • Website: www.gtcbio.com/conference/stem-cell-summit-overview

GTC Diabetes Summit

  • Date and Time: Thursday, April 24, 2014, 4:15 PM EDT
  • Venue: Hyatt Regency Cambridge, 575 Memorial Drive, Cambridge, MA
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Partnering Opportunities in Diabetes Drug Development - Autologous Cell Therapy: Leveraging Innate Tissue Repair Capacity to Modify Disease Natural History
  • Website: www.gtcbio.com/conference/diabetes-summit-overview

ISCT 2014 – 20th Annual Meeting

  • Date and Time: Friday, April 25, 2014 10:45 AM CET
  • Venue: Le Palais des Congrès de Paris, Paris, France
  • Speaker: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Strategies for Commercialization: Managing COGs and the Impact of Product Decisions from Phase I to Commercial Supply
  • Website: www.isct2014.com

Poster presentation at ISCT 2014

  • Poster Title: "Characterization of bone marrow-derived CD34+ cells with different migratory potential by microRNA fingerprinting and antibody array."
  • Date and Time: Thursday, April 24, 2014 5:00 - 6:30 PM CET (Poster Hall)
  • Presenter: Dr. Courtney LeBlon, Process Development Scientist, PCT

2014 Allicense Conference

  • Date: Wednesday, April 30, 2014
  • Venue: Palace Hotel, San Francisco, CA
  • Speaker: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Session #1: Keynote Address: Leveraging the Public Markets to Finance Development (9:10 AM PDT)
  • Session #2: Panel on Public Markets (11:30 AM PDT)
  • Website: www.allicense.com

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's ability to develop and grow its business, the successful development of cellular therapies, including with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's CD34 Cell Program, T Regulatory Cell Program, VSEL™ Technology for tissue regeneration and other cell therapies, including the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Investor Contact: LifeSci Advisors, LLC Michael Rice Founding Partner Phone: +1-646-597-6979 Email: mrice@lifesciadvisors.com Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email: epowers@neostem.com

Source:NeoStem Inc.